Edition:
United States

Mylan NV (MYL.O)

MYL.O on Nasdaq

32.21USD
19 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$32.21
Open
--
Day's High
--
Day's Low
--
Volume
129
Avg. Vol
4,453,231
52-wk High
$47.82
52-wk Low
$31.54

Chart for

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.35
Market Cap(Mil.): $20,534.19
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.O Industry Sector
P/E (TTM): 31.22 30.90 33.64
EPS (TTM): 1.23 -- --
ROI: 2.39 14.75 14.27
ROE: 5.71 16.24 15.99

Plaintiffs seek sanctions against Mylan in EpiPen litigation

Lawyers for consumers who accuse Mylan NV of engaging in an unlawful scheme to squelch competition for its EpiPen allergy treatment have asked a federal judge to sanction the drugmaker for interfering with subpoenas they issued to its vendors.

Oct 02 2018

Mylan, Fujifilm win EU okay for copy of AbbVie's Humira

LONDON, Sept 20 Mylan and Fujifilm Kyowa Kirin Biologics said on Thursday they had won European approval to market a cheaper copy of AbbVie's $18-billion-a-year biologic drug Humira, the world's best-selling prescription medicine.

Sep 20 2018

BRIEF-Mylan Closes Deal With Novartis To Commercialize Certain Global Cystic Fibrosis Products

* MYLAN - CLOSED DEAL WITH NOVARTIS TO BUY WORLDWIDE RIGHTS TO COMMERCIALIZE GLOBAL CYSTIC FIBROSIS PRODUCTS CONSISTING OF TOBI PODHALER & TOBI SOLUTION Source text for Eikon: (https://bit.ly/2oJcNd7) Further company coverage:

Sep 05 2018

Mylan, Pfizer must face consumer lawsuit over EpiPen: judge

A federal judge has rejected Mylan NV's bid to escape a proposed class action lawsuit accusing the drugmaker of engaging in an unlawful scheme to squelch competition for its EpiPen allergy treatment, allowing it to unjustifiably raise its prices.

Aug 21 2018

FDA extends EpiPen expiry date to combat shortage

The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

Aug 21 2018

U.S. FDA extends EpiPen expiry date to combat shortage

Aug 21 The U.S. Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan NV's EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

Aug 21 2018

FDA approves Teva's generic of Mylan's EpiPen

The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs. | Video

Aug 18 2018

UPDATE 2-U.S. FDA approves Teva's generic of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's life-saving allergy injection, EpiPen, at a time when regulators are looking to lower healthcare costs.

Aug 16 2018

U.S. FDA approves first generic version of Mylan's EpiPen

Aug 16 The U.S. Food and Drug Administration on Thursday approved Teva Pharmaceutical Industries Ltd's generic version of Mylan NV's EpiPen for the emergency treatment of allergic reactions.

Aug 16 2018

Wall Street dragged down by fall out from Turkey's plunging lira

NEW YORK U.S. stocks dropped on Monday as global jitters from Turkey's plummeting currency spread to Wall Street, with the S&P 500 and the Dow falling for the fourth session in a row. | Video

Aug 13 2018

Earnings vs. Estimates